Development of Chinese Population Medicines Using Population Genetics and Artificial Intelligence

Bin Cong; Wanxian Wang

doi:10.1016/j.eng.2026.05.008

Engineering ›› :202605008 DOI: 10.1016/j.eng.2026.05.008

research-article

Development of Chinese Population Medicines Using Population Genetics and Artificial Intelligence

Bin Cong ^a^,^b^,^c^,^#^,^*
, Wanxian Wang ^a^,^d^,^#

Author information +

History +

PDF (1217KB)

Abstract

Cite this article

Download citation ▾

Bin Cong, Wanxian Wang. Development of Chinese Population Medicines Using Population Genetics and Artificial Intelligence. Engineering 202605008 DOI:10.1016/j.eng.2026.05.008

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Holden C . Race and medicine. Science 2003; 302(5645):594-6.

[2]	Biswas M, Jinda P, Sukasem C . Pharmacogenomics in Asians: differences and similarities with other human populations. Expert Opin Drug Metab Toxicol 2023; 19(1):27-41.

[3]	Zhao FL, Zhang Q, Wang SH, Hong Y, Zhou S, Zhou Q, et al. Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C972—75 in the Chinese Han population. Front Pharmacol 2022; 13:1007268.

[4]	Wolf CR, Smith G . Pharmacogenetics. Br Med Bull 1999; 55(2):366-86.

[5]	Al—Kaif MA, Daud NAA, Sha’aban A, Ng ML, Abdul Kader MAS, Noor DAM, et al. The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD). Molecules 2021; 26(7):1987.

[6]	Ortega VE, Meyers DA . Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol 2014; 133(1):16-26.

[7]	Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet 2020; 52(2):177-86.

[8]	Ohara M, Suzuki Y, Shinohara S, Gong IY, Schmerk CL, Tirona RG, et al. Differences in warfarin pharmacodynamics and predictors of response among three racial populations. Clin Pharmacokinet 2019; 58(8):1077-89.

[9]	Caraco Y, Lagerstrom PO, Wood AJ . Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60(2):157-67.

[10]	Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol 2015; 71(3):329-40.

[11]	Lo C, Nguyen S, Yang C, Witt L, Wen A, Liao TV, et al. Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications. Clin Transl Sci 2020; 13(5):861-70.

[12]

Lee MMY, Ghouri N, Misra A, Kang YM, Rutter MK, Gerstein HC, et al. Comparative efficacy of glucagon—like peptide 1 receptor agonists for cardiovascular outcomes in Asian versus White populations: systematic review and meta—analysis of randomized trials of populations with or without type 2 diabetes and/or overweight or obesity. Diabetes Care 2025; 48(3):489-93.

[13]	Qian J, Nie W, Lu J, Zhang L, Zhang Y, Zhang B, et al. Racial differences in characteristics and prognoses between Asian and White patients with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies. Int J Cancer 2020; 146(11):3124-33.

[14]	Atasilp C, Biswas M, Jinda P, Nuntharadthanaphong N, Rachanakul J, Hongkaew Y, et al. Association of UGT1A16, 28 or ABCC2 c.3972C>T genetic polymorphisms with irinotecan—induced toxicity in Asian cancer patients: meta—analysis. Clin Transl Sci 2022; 15(7):1613-33.

[15]	Cong B, Chen XM . Epistemology and methodology of integrating Chinese and Western medicine. Chin J Integr Tradit West Med 2021; 41(6):742—7.

[16]	Liu Y, Ding X, Younas A, Sun X, Ni X, Wang S, et al. Xiaoyao San’s dual efficacy in NAFLD and depression: unraveling the mechanisms via network pharmacology and multi—omics. Phytomedicine 2025; 147:157221.

[17]	Lei T, Fu G, Xue X, Yang H . Tianma Gouteng Decoction improve neuronal synaptic plasticity and oligodendrocyte apoptosis in Parkinson’s disease mice. Phytomedicine 2025; 140:156553.

[18]	Wang B, Kong D, Yang Z, Kang J, Sun D, Duan X, et al. Revealing the mechanisms of compound Kushen injection on oxidative stress regulation in the treatment of radiation—induced lung injury. Engineering 2025; 55:254-68.

[19]	Zhu C, Cai T, Jin Y, Chen J, Liu G, Xu N, et al. Artificial intelligence and network pharmacology based investigation of pharmacological mechanism and substance basis of Xiaokewan in treating diabetes. Pharmacol Res 2020; 159:104935.

[20]	Hu Z, Jia J, Su Y, Gu Y, Cheng B, Jiang N . Modified Zexie Decoction improves phlegm—dampness type stage I hypertension by regulating the gut—immune—kidney axis. Front Pharmacol 2025; 16:1578815.

[21]	Jiao Z, Zheng J, Yang X, Ruan Q, Ma Y, Huang Y, et al. Yangweishu ameliorates chronic atrophic gastritis with stomach Yin deficiency syndrome through IL—6/STAT3 signaling pathway. Drug Des Devel Ther 2025; 19:7865-85.

[22]	Zhu K, Guo Y, Zhao C, Kang S, Li J, Wang J, et al. Etiology exploration of non—alcoholic fatty liver disease from traditional Chinese medicine constitution perspective: a cross—sectional study. Front Public Health 2021; 9:635818.

[23]	Sun Z, Ping P, Li Y, Feng L, Liu F, Zhao Y, et al. Relationships between traditional Chinese medicine constitution and age—related cognitive decline in Chinese centenarians. Front Aging Neurosci 2022; 14:870442.

[24]	Tu Y . The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011; 17(10):1217—20.

[25]	Yang L, Zhou X, Liu J, Yang G, Tan W, Ding H, et al. PEBL, a component—based Chinese medicine, reduces virus—induced acute lung injury by targeting FXR to decrease ACE2 levels. J Adv Res 2026; 80:1099-119.

[26]	Lindeboom RGH, Regev A, Teichmann SA . Towards a human cell atlas: taking notes from the past. Trends Genet 2021; 37(7):625—30.

[27]	Cong B, Li L, Wang Q, He T, Li J, Xie H, et al. Cellular chemical field and cellular homeostasis. Engineering 2024; 39:18-24.

[28]	He X, Li R, He X, He F, Xiao Y, Chen X, et al. Elucidation of the anti—arthritic mechanism of Guizhi—Shaoyao—Zhimu Decoction by reshaping circadian rhythm. Pharmacol Res 2025; 216:107787.

[29]	Ni JN, Wei MQ, Li T, Shi J, Xiao W, Cheng J, et al. Development of a new paradigm for precision diagnosis and treatment of traditional Chinese medicine. J Beijing Univ Tradit Chin Med 2025; 48(1):43-7.

[30]	Hey AJG, Tansley S, Tolle KM, editors. The fourth paradigm: data—intensive scientific discovery. Redmond: Microsoft Research; 2009.

[31]	Jiang Y, Zhu S, Tang J . Large population—based cohorts: essential platforms for medical research. Inn Med 2026; 4(1):100178.

[32]	Wang H, Fu T, Du Y, Gao W, Huang K, Liu Z, et al. Scientific discovery in the age of artificial intelligence. Nature 2023; 620(7972):47-60.

[33]	Cong B, Liu X, Zhang S, Ni Z, Wang L . Revolutionizing the life sciences by developing a holographic digital mannequin. Engineering 2023; 27:14-7.

[34]	Zhang P, Zhang D, Zhou W, Wang L, Wang B, Zhang T, et al. Network pharmacology: towards the artificial intelligence—based precision traditional Chinese medicine. Brief Bioinform 2023; 25(1):bbad518.

[35]	Venkatapurapu SP, Clegg L, Nowojewski A, Kimko H, Olabode D, Sawant—Basak A, et al. Digital twins for accelerating drug discovery and development: opportunities and challenges. Drug Discov Today 2026; 31(2):104617.

[36]	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) . ICH topic E5(R1): ethnic factors in the acceptability of foreign clinical data. London: ICH; 1998.

[37]	National Medical Products Administration (NMPA) . Technical guidelines for the acceptance of overseas clinical trial data of drugs. Beijing: NMPA; 2018.